The race to develop a vaccine for the world's fastest-spreading Ebola strain is a critical endeavor, and the efforts are being led by organizations like the Coalition for Epidemic Preparedness Innovations (Cepi). The Bundibugyo strain, first detected in Uganda in 2007, is currently spreading rapidly across northeastern and eastern Democratic Republic of the Congo, with no approved vaccines available. Cepi is backing four vaccine candidates through their testing phase, with initial results expected in late September or early October. These candidates are Oxford University and the Serum Institute of India's ChAdOx1 BDBV, Moderna's mRNA-1469, and a vaccine modeled on Merck's Ervebo vaccine for the Ebola Zaire strain. The rapid development and testing of these vaccines demonstrate the flexibility and efficiency of working with established partners and mobilizing funding. However, the outbreak has quickly become a live test case of the 100 days mission, a Cepi-led initiative that aims to rapidly deliver vaccines, diagnostics, and therapeutics when a new pathogen emerges. Despite the ambitious target, there is progress, and Cepi's new strategy focuses on understanding critical scientific and logistical bottlenecks to speed up vaccine delivery. The outbreak has also raised concerns about mistrust among the population, which has complicated the response, including for a future vaccine rollout. To address this, Cepi relies on organizations like the International Federation of Red Cross and Red Crescent Societies (IFRC) to work with communities on building trust. On the diplomatic front, negotiations on the specifics of a system under the pandemic agreement for governments to exchange pathogen data have stalled. Cepi is one of the technical experts advising negotiations, and the organization believes that a deal is necessary, even if it isn't perfect. The funding for global health has also been struggling due to aid cuts, and Cepi's funding, largely from western donors and philanthropic powerhouses, has held steady. However, the organization worries about the wider sector, as the chances of another pandemic in our lifetimes are more than not. The economic fallout of the Ebola outbreak will have a significant impact on a population battered by decades of health crises and conflict, and the annual cost of pandemic risk is estimated to be over $700 billion. The race to develop a vaccine is a critical endeavor, and the efforts are being led by organizations like Cepi, but the challenges are significant, and the future of global health depends on the success of these efforts.
